A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 381 participants.
Also called NCT05261126
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 381 participants
- Sponsor
- Registry
-
NCT05261126 -
jRCT2031210701 -
2021-005221-24
-
- Main results
- Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Germany, Japan, Mexico, Norway, South Korea, Türkiye, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05261126. Randomized; double masking; primary purpose treatment. Start 2022-03-10 (actual); primary completion 2022-11-28 (actual). Results posted on 2023-12-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)
- Condition
- Hypercholesterolemia
- Condition
- Familial Hypercholesterolemia
- Intervention (Drug)
- Enclitide Chloride
- Intervention (Drug)
- Placebo
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct05261126- Content hash
2fea1ccc43e35ded95aa6ec2a2e4299e25a659f7e9837a5b317fcfa893f26296